NPS Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference

Business Wirevia The Motley Fool
Updated

NPS Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference

BEDMINSTER, N.J.--(BUSINESS WIRE)-- NPS Pharmaceuticals, Inc. (NAS: NPSP) will present at the Morgan Stanley 2013 Global Healthcare Conference in New York on Monday, September 9, 2013 at 11:45 a.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the investors' calendar of events page on the NPS website at http://www.npsp.com/calendar.

About NPS Pharmaceuticals


NPS Pharmaceuticals is a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The company's lead product, Gattex® (U.S.)/Revestive® (ex-U.S.) (teduglutide [rDNA origin]) for injection is approved for adult Short Bowel Syndrome (SBS) patients who are dependent on parenteral support. NPS has also developed Natpara® (rhPTH [1-84]) for the treatment of adult hypoparathyroidism and expects to submit its marketing application to the U.S. Food and Drug Administration in the fourth quarter of 2013. NPS's earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia (ADH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, and Kyowa Hakko Kirin.



NPS Pharmaceuticals, Inc.
Gail Brophy, 908-450-5335

KEYWORDS: United States North America New Jersey New York

INDUSTRY KEYWORDS:

The article NPS Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement